NCT06770504
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
At risk: Primary completion moved 1 year 6 months later.
See at-risk trials from Institute of Hematology & Blood Diseases Hospital, China
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Dec 30, 2025 to Jun 30, 2027 Show 5 more changesShow less
- Eligibility criteria expanded, about 25 words
- Trial status changed: Not Yet Recruiting → Active, Not Recruiting
- Study completion pushed from Dec 30, 2026 to Dec 30, 2027
- Study sites: 0 to 1
- Start date changed from estimate of Jan 16, 2025 to Feb 26, 2025
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Dose Limiting Toxicity
Timeframe: Within 28 days after infusion
The incidence and frequency of treatment-emergent adverse events
Timeframe: Within 12 months after infusion
Best overall response rate (BOR) of each dose group
Timeframe: Within 12 weeks after infusion
Objective response rate (ORR) of each dose group
Timeframe: Within 4 weeks after infusion
Time to response (TTR)
Timeframe: Within 6 months after infusion
Arms and interventions
YTS109Experimental
Participants will receive YTS109 cell infusion after preconditioning, and they need to be closely monitored for 24 hours following START-T cell infusion.
Biologicals: YTS109
Sites
1 site in 1 country
- Regenerative Medicine CenterTianjin, Tianjin Municipality, China